Interior hero background

Current Clinical Trials


  • This is an international, multicenter, parallel-group, randomized, double-blind, placebo-controlled trial in patients who have been stabilized during hospitalization for acute heart failure, evaluating the effect of in-hospital initiation of dapagliflozin versus placebo on the clinical outcome of cardiovascular death or worsening heart failure.
  • A Randomized, Double-blind, Placebo-controlled Trial Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT)
  • A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT)


  • Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer


  • Blood
    • A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusion-related Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous)
  • Breast
    • TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer.
    • Mepitel Film for the Reduction of Radiation Dermatitis in Breast Cancer Patients Undergoing Post-Mastectomy Radiation Therapy: A Randomized Phase III Clinical Trial
    • Evaluation of Lasofoxifene Combine with Abemaciclib Compared with Fulvestrant Combined with Abemaciclib in Locally Advanced or Metatstatic ER+/HR2- Breast Cancer with an ESR1 Mutation
    • DEBRA: De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer
  • Kidney
    • Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study.
  • Lung
    • This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab with SoC SBRT versus placebo with SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3N0M0) NSCLC.
    • MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK).
    • Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer
    • A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants with Non-Small Cell Lung Cancer
  • Prostate
    • This phase II trial compares the effect of oxybutynin versus placebo for reducing hot flashes in men receiving androgen deprivation (hormone) therapy for the treatment of prostate cancer. Androgen deprivation therapy decreases testosterone and other androgens through medications or surgical removal of the testicles. Relative to placebo, low- or high-dose oxybutynin may reduce hot flashes in men receiving androgen deprivation therapy.
    • Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE).
    • Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
    • Relugolix Versus Leuprolide in Patients With Prostate Cancer: A Randomized, Open-Label Study to Assess Major Adverse Cardiovascular Events (REPLACE-CV)
  • Supportive Care
    • A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia.
    • A Randomized Phase III Trial of Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy


  • The Vallania Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening
  • The PROACT LUNG Study: A Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
  • Study ID: PROACT
  • Principle Investigator: Grant Seeger, MD

You can learn more about clinical trials by visiting, which is a database of privately and publicly funded clinical studies conducted around the world. 

Contact Us

Altru Health System, Research
1380 South Columbia Road
Grand Forks, ND 58201
Phone: 701.780.5195

4 Fall Activities to Keep You Active & Happy

Health & Wellness

4 Fall Activities to Keep You Active & Happy

September 22, 2023

Health & Wellness

Tongue Tie & Lip Tie Diagnosis, Treatment & Development

October 25, 2023

Health & Wellness

5 Ways to Cope with a Cancer Diagnosis

October 6, 2023

Health & Wellness

Vasectomy Procedure: What to Expect Before, During & After

November 30, 2023
5 Reasons You Need a Primary Care Physician

Health & Wellness

5 Reasons You Need a Primary Care Physician

March 10, 2023